Latest Content

In CATNON, 12 cycles after radiation extended median survival past 12 years in IDH-mutant disease while concurrent dosing showed no benefit.

Dr. Sue Hwang explains how she went from a care provider who helped others through their cancer journeys to a patient facing a cancer diagnosis of her own.

Drs. Miller, Orringer and Yang explain IDH testing, treatment options, quality of life and caregiver roles for patients with IDH-mutant glioma.

Merkel cell carcinoma is a rare and aggressive form of neuroendocrine skin cancer. While it accounts for a small fraction of all skin cancer cases, its impact is significant.

USC doctors say careful staging and tumor testing help younger patients choose surgery and targeted treatments based on their cancer.

Hodgkin lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen and immune cells that help the body fight infection.

Stage 3 ccRCC is locally advanced but often treatable. Learn how it is diagnosed, treated, and managed to support informed decisions with your care team.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

I never thought about mantras until my diagnosis with colon cancer at the age of 34.

Dr. Jesse Miller Lewin sat down with CURE to discuss how advances in systemic and local therapies are reshaping the treatment landscape for skin cancer.

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA has granted orphan drug designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.

FDA expands access to CAR-T cell therapy for patients with relapsed or refractory PCNSL.